News RSS Bioethics News.

10/30/2018

Amgen Slashes the Price of a Promising Cholesterol Drug

External Link - Source: New York Times

Insurers have been reluctant to broadly cover the drugs, instead requiring patients and their doctors to demonstrate why the patients could not instead take the cheaper alternative — statins. The drug companies have fought back, enlisting the help of patient advocacy groups that receive donations from the manufacturers to make the point that the insurers’ restrictions are unfair.